Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes

How we treat lower-risk myelodysplastic syndromes

(2013) P. Fenaux et al.   BLOOD

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

(2013) F. Ravandi et al.   BLOOD

Gender, Cytidine Deaminase, and 5-Aza/Decitabine--Response

(2013) R. Z. Mahfouz et al.   CLINICAL CANCER RESEARCH

Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy

(2013) R. Z. Mahfouz et al.   CLINICAL CANCER RESEARCH

Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia

(2013) Maria Teresa Voso et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

(2013) S. D. Gore et al.   HAEMATOLOGICA

Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): A report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM)

(2013) Cecile Bally et al.   LEUKEMIA RESEARCH

Epigenetic action of decitabine (5-aza-2′-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C)

(2013) Richard L. Momparler et al.   LEUKEMIA RESEARCH

Polycomb segment myeloid malignancies

(2012) Y. Saunthararajah et al.   BLOOD

Predicting survival of patients with hypocellular myelodysplastic syndrome

(2012) Wei-Gang Tong et al.   CANCER

Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells

(2012) Hsing-Chen Tsai et al.   CANCER CELL

A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine

(2012) Peter L. Greenberg et al.   LEUKEMIA & LYMPHOMA

Molecular Roadblocks for Cellular Reprogramming

(2012) Thomas Vierbuchen et al.   MOLECULAR CELL

Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia

(2012) Matthew J. Olnes et al.   NEW ENGLAND JOURNAL OF MEDICINE

p53-Independent, Normal Stem Cell Sparing Epigenetic Differentiation Therapy for Myeloid and Other Malignancies

(2012) Yogen Saunthararajah et al.   SEMINARS IN ONCOLOGY

Concise Review: Hematopoietic Stem Cell Aging, Life Span, and Transplantation

(2012) Gary Van Zant et al.   Stem Cells Translational Medicine

Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine

(2011) D. Lavelle et al.   BLOOD

RUNX1 regulates corepressor interactions of PU.1

(2011) Z. Hu et al.   BLOOD

A pilot study of subcutaneous decitabine in  -thalassemia intermedia

(2011) N. F. Olivieri et al.   BLOOD

Telomere biology in hematopoiesis and stem cell transplantation

(2011) Shahinaz M. Gadalla et al.   BLOOD REVIEWS

Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia

(2011) Guillermo Garcia-Manero et al.   JOURNAL OF CLINICAL ONCOLOGY

Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

(2011) Michael Lübbert et al.   JOURNAL OF CLINICAL ONCOLOGY

p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia

(2011) K P Ng et al.   LEUKEMIA

CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors

(2011) S Negrotto et al.   LEUKEMIA

p53 Lesions in Leukemic Transformation

(2011) Ashot Harutyunyan et al.   NEW ENGLAND JOURNAL OF MEDICINE

New Ways to Use DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic Syndrome

(2011) S. D. Gore   Hematology-American Society of Hematology Education Program

Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy

(2010) H. M. Kantarjian et al.   BLOOD

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

(2010) R. Itzykson et al.   BLOOD

Decitabine Maintains Hematopoietic Precursor Self-Renewal by Preventing Repression of Stem Cell Genes by a Differentiation-Inducing Stimulus

(2010) Z. Hu et al.   MOLECULAR CANCER THERAPEUTICS

Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes

(2009) Roger M. Lyons et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial

(2009) David P. Steensma et al.   JOURNAL OF CLINICAL ONCOLOGY

Epigenetic Therapies Move Into New Territory, but How Exactly Do They Work?

(2009) R. S. Tuma   JNCI-Journal of the National Cancer Institute

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine

(2008) Gautam Borthakur et al.   LEUKEMIA & LYMPHOMA